Mar. 20 at 3:27 PM
$CCCC | The “Avengers” of targeted protein degradation—MRK, PFE, BIIB, RHHBY all in.
👉If this is helpful to you, tap @NasdaqKnight
C4 Therapeutics isn’t a lottery ticket. It’s a platform-backed biotech with an absurd partnership roster.
Confirmed collaborations
$MRK /
$PFE /
$BIIB /
$RHHBY / Betta
— Every major pharma wants access to their TPD platform. This level of multi-party validation is rare in small-cap biotech.
Price targets
Wells Fargo PT:
$10
Bull case:
$21
Upside from current levels: 250%+ (even the base case implies a double)
M&A angle
In a market hungry for de-risked platforms,
$CCCC checks every box: differentiated science, marquee partnerships, and a market cap that fits Big Pharma’s acquisition range. This is a legitimate takeout candidate.
⚠️ Risks exist (clinical data, cash runway), but when you see this lineup of partners, you know institutional due diligence is already priced in.
